MDMAI (5-iodo-MDAI)
5-iodo-MDAI is an iodinated analog of the serotonin-selective aminoindane entactogen MDAI. It is essentially uncharacterised in humans and expected to produce gentle MDMA-like emotional effects with minimal stimulation, while retaining serotonin-syndrome risk shared by the aminoindane class.
01 Overview
5-iodo-MDAI extends the aminoindane entactogen family (MDAI, MMAI) with a ring iodine substituent, a modification used in research to probe serotonin-transporter interactions. By analogy it should behave as a serotonin-selective releaser giving soft empathogenic effects with little stimulation.
There is virtually no human pharmacology or safety data. Even serotonin-selective aminoindanes carry serotonin-syndrome risk and unknown long-term effects. Likely covered by analog or psychoactive-substances legislation.
02 Mechanism
Iodinated aminoindane acting as a selective serotonin-releasing agent at the serotonin transporter with minimal dopaminergic action.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 50–100 mg | Oral | Estimated by analogy to MDAI; unverified |
| Common | 100–180 mg | Oral | Estimated, high uncertainty |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Mild entactogenesisExpected gentle emotional openness by analogy to MDAI; direct reports scarce. | Presumed mild | Unconfirmed | |
| Low stimulationSerotonin-selective profile implies little stimulation. | Minimal | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeSerotonin release can precipitate serotonin toxicity, particularly in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Unconfirmed | |
| Uncharacterised safetyNo human toxicology exists for this obscure iodinated compound. | Moderate | Uncharacterised | Unconfirmed |